Clinical Trials Logo

Clinical Trial Summary

Subanesthetic ketamine is currently used as a rapid-acting antidepressant. It is an antagonist of the N-methyl-d-aspartate (NMDA) receptor, but former results indicate that its action also depends on the noradrenaline system and the locus coeruleus (LC). Based on this known impact of ketamine on the sympathetic nervous system the aim of this study is to investigate the effects of intranasal esketamine on LC related attentional brain networks in task based functional MRI, to relate those attention network changes to behavioural measures and to predict ketamine related attention network changes by brain structure.


Clinical Trial Description

n/a


Study Design


NCT number NCT05320120
Study type Interventional
Source Medical University of Vienna
Contact
Status Completed
Phase Phase 1
Start date June 1, 2022
Completion date June 21, 2023